124 related articles for article (PubMed ID: 38432233)
1. Effect of tebipenem pivoxil hydrobromide on the normal gut microbiota of a healthy adult population in Sweden: a randomised controlled trial.
Sewunet T; Razavi M; Rosenborg S; Camporeale A; Nowak M; Melnick D; Gasink LB; Eckburg PB; Critchley IA; Nord CE; Giske CG
Lancet Microbe; 2024 Apr; 5(4):e355-e365. PubMed ID: 38432233
[TBL] [Abstract][Full Text] [Related]
2. Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.
Eckburg PB; Muir L; Critchley IA; Walpole S; Kwak H; Phelan AM; Moore G; Jain A; Keutzer T; Dane A; Melnick D; Talley AK
N Engl J Med; 2022 Apr; 386(14):1327-1338. PubMed ID: 35388666
[TBL] [Abstract][Full Text] [Related]
3. Tebipenem pivoxil hydrobromide-No PICC, no problem!
Sodhi V; Kronsberg KA; Clark M; Cho JC
Pharmacotherapy; 2021 Sep; 41(9):748-761. PubMed ID: 34370326
[TBL] [Abstract][Full Text] [Related]
4. Impact of oral amoxicillin and amoxicillin/clavulanic acid treatment on bacterial diversity and β-lactam resistance in the canine faecal microbiota.
Espinosa-Gongora C; Jessen LR; Kieler IN; Damborg P; Bjørnvad CR; Gudeta DD; Pires Dos Santos T; Sablier-Gallis F; Sayah-Jeanne S; Corbel T; Nevière A; Hugon P; Saint-Lu N; de Gunzburg J; Guardabassi L
J Antimicrob Chemother; 2020 Feb; 75(2):351-361. PubMed ID: 31778166
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.
Keij FM; Kornelisse RF; Hartwig NG; van der Sluijs-Bens J; van Beek RHT; van Driel A; van Rooij LGM; van Dalen-Vink I; Driessen GJA; Kenter S; von Lindern JS; Eijkemans M; Stam-Stigter GM; Qi H; van den Berg MM; Baartmans MGA; van der Meer-Kappelle LH; Meijssen CB; Norbruis OF; Heidema J; van Rossem MC; den Butter PCP; Allegaert K; Reiss IKM; Tramper-Stranders GA
Lancet Child Adolesc Health; 2022 Nov; 6(11):799-809. PubMed ID: 36088952
[TBL] [Abstract][Full Text] [Related]
6. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
7. Safety, Pharmacokinetics, and Food Effect of Tebipenem Pivoxil Hydrobromide after Single and Multiple Ascending Oral Doses in Healthy Adult Subjects.
Eckburg PB; Jain A; Walpole S; Moore G; Utley L; Manyak E; Dane A; Melnick D
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262768
[TBL] [Abstract][Full Text] [Related]
8. Plasma and Intrapulmonary Concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to Healthy Adult Subjects.
Rodvold KA; Gotfried MH; Gupta V; Ek A; Srivastava P; Talley A; Bruss J
Antimicrob Agents Chemother; 2022 Jul; 66(7):e0059022. PubMed ID: 35762796
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and soft-tissue distribution of tebipenem pivoxil hydrobromide using microdialysis: a study in healthy subjects and patients with diabetic foot infections.
Abouelhassan Y; Fratoni AJ; Shepard AK; Nicolau DP; Asempa TE
J Antimicrob Chemother; 2022 Dec; 78(1):296-301. PubMed ID: 36424364
[TBL] [Abstract][Full Text] [Related]
10. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Liou JM; Chen CC; Chang CM; Fang YJ; Bair MJ; Chen PY; Chang CY; Hsu YC; Chen MJ; Chen CC; Lee JY; Yang TH; Luo JC; Chen CY; Hsu WF; Chen YN; Wu JY; Lin JT; Lu TP; Chuang EY; El-Omar EM; Wu MS;
Lancet Infect Dis; 2019 Oct; 19(10):1109-1120. PubMed ID: 31559966
[TBL] [Abstract][Full Text] [Related]
11. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
12. Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential.
Bulow C; Langdon A; Hink T; Wallace M; Reske KA; Patel S; Sun X; Seiler S; Jones S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2018 Nov; 3(6):. PubMed ID: 30463925
[TBL] [Abstract][Full Text] [Related]
13.
Cotroneo N; Rubio A; Critchley IA; Pillar C; Pucci MJ
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423950
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetic Analyses for Tebipenem after Oral Administration of Pro-Drug Tebipenem Pivoxil Hydrobromide.
Ganesan H; Gupta VK; Safir MC; Bhavnani SM; Talley AK; Melnick D; Rubino CM
Antimicrob Agents Chemother; 2023 Jun; 67(6):e0145122. PubMed ID: 37191505
[TBL] [Abstract][Full Text] [Related]
15. Pivmecillinam with Amoxicillin/Clavulanic acid as step down oral therapy in febrile Urinary Tract Infections caused by ESBL-producing Enterobacterales (PACUTI).
Tverring J; Månsson E; Andrews V; Ljungquist O
Trials; 2023 Sep; 24(1):568. PubMed ID: 37660037
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trial.
Poachanukoon O; Kitcharoensakkul M
Clin Ther; 2008 Oct; 30(10):1870-9. PubMed ID: 19014842
[TBL] [Abstract][Full Text] [Related]
17. Oral clindamycin 300 mg BID compared with oral amoxicillin/clavulanic acid 1 g BID in the outpatient treatment of acute recurrent pharyngotonsillitis caused by group a beta-hemolytic streptococci: an international, multicenter, randomized, investigator-blinded, prospective trial in patients between the ages of 12 and 60 years.
Mahakit P; Vicente JG; Butt DI; Angeli G; Bansal S; Zambrano D
Clin Ther; 2006 Jan; 28(1):99-109. PubMed ID: 16490583
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Tebipenem Hydrolysis by β-Lactamases Prevalent in Complicated Urinary Tract Infections.
Sun Z; Su L; Cotroneo N; Critchley I; Pucci M; Jain A; Palzkill T
Antimicrob Agents Chemother; 2022 May; 66(5):e0239621. PubMed ID: 35491852
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial.
Goyal V; Grimwood K; Ware RS; Byrnes CA; Morris PS; Masters IB; McCallum GB; Binks MJ; Smith-Vaughan H; O'Grady KF; Champion A; Buntain HM; Schultz A; Chatfield M; Torzillo PJ; Chang AB
Lancet Respir Med; 2019 Sep; 7(9):791-801. PubMed ID: 31427252
[TBL] [Abstract][Full Text] [Related]
20. The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant
Fernández Álvaro E; Voong Vinh P; de Cozar C; Willé DR; Urones B; Cortés A; Price A; Tran Do Hoang N; Ha Thanh T; McCloskey M; Shaheen S; Dayao D; Martinot A; de Mercado J; Castañeda P; García-Perez A; Singa B; Pavlinac P; Walson J; Martínez-Martínez MS; Arnold SLM; Tzipori S; Ballell Pages L; Baker S
Elife; 2022 Mar; 11():. PubMed ID: 35289746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
